Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites
Daniel R Feikin,Eunice W Kagucia,Jennifer D Loo,Ruth Link-Gelles,Milo A Puhan,Thomas Cherian,Orin S Levine,Cynthia G Whitney,Katherine L O'Brien,Matthew R Moore,Serotype Replacement Study Group,Claire A Adegbola,Mary Agocs,Krow Ampofo,Nick Andrews,Theresa Barton,Javier Benito,Claire V Broome,Michael G Bruce,Lisa R Bulkow,Carrie L Byington,Teresa Camou,Heather Cook,Suzanne Cotter,Ron Dagan,Philippe De Wals,Geneviève Deceuninck,Barbara Denham,Giles Edwards,Juhani Eskola,Margaret Fitzgerald,Emmanouil Galanakis,Gabriela Garcia-Gabarrot,Juan J Garcia-Garcia,Amadeu Gene,Borja Gomez,Helen Heffernan,Thomas W Hennessy,Sigrid Heuberger,Markus Hilty,Helene Ingels,Sanjay Jayasinghe,James D Kellner,Nicola P Klein,Andrea Kormann-Klement,Jana Kozakova,Vicki Krause,Paula Kriz,Lotte Lambertsen,Agnès Lepoutre,Marc Lipsitch,Mariana Lopez-Vega,Marguerite Lovgren,Sofia Maraki,Edward O Mason,Peter B McIntyre,Robert Menzies,Allison Messina,Elizabeth Miller,Santiago Mintegi,Jitka Motlova,Lawrence H Moulton,Kathrin Mühlemann,Carmen Muñoz-Almagro,David R Murdoch,Daniel E Park,Arthur L Reingold,Raquel Sa-Leao,Abanti Sanyal,Peter G Smith,Lodewijk Spanjaard,Chonnamet Techasaensiri,Richard E Thompson,Koh C Thoon,Gregory J Tyrrell,Palle Valentiner-Branth,Arie van der Ende,Otto G Vanderkooi,Mark P G van der Linden,Emmanuelle Varon,Jan Verhaegen,Didrik F Vestrheim,Imelda Vickers,Anne von Gottberg,Rüdiger von Kries,Pauline Waight,Robert Weatherholtz,Susanne Weiss,Arnold Yee,Anita K M Zaidi
DOI: https://doi.org/10.1371/journal.pmed.1001517
Abstract:Background: Vaccine-serotype (VT) invasive pneumococcal disease (IPD) rates declined substantially following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into national immunization programs. Increases in non-vaccine-serotype (NVT) IPD rates occurred in some sites, presumably representing serotype replacement. We used a standardized approach to describe serotype-specific IPD changes among multiple sites after PCV7 introduction. Methods and findings: Of 32 IPD surveillance datasets received, we identified 21 eligible databases with rate data ≥ 2 years before and ≥ 1 year after PCV7 introduction. Expected annual rates of IPD absent PCV7 introduction were estimated by extrapolation using either Poisson regression modeling of pre-PCV7 rates or averaging pre-PCV7 rates. To estimate whether changes in rates had occurred following PCV7 introduction, we calculated site specific rate ratios by dividing observed by expected IPD rates for each post-PCV7 year. We calculated summary rate ratios (RRs) using random effects meta-analysis. For children <5 years old, overall IPD decreased by year 1 post-PCV7 (RR 0.55, 95% CI 0.46-0.65) and remained relatively stable through year 7 (RR 0.49, 95% CI 0.35-0.68). Point estimates for VT IPD decreased annually through year 7 (RR 0.03, 95% CI 0.01-0.10), while NVT IPD increased (year 7 RR 2.81, 95% CI 2.12-3.71). Among adults, decreases in overall IPD also occurred but were smaller and more variable by site than among children. At year 7 after introduction, significant reductions were observed (18-49 year-olds [RR 0.52, 95% CI 0.29-0.91], 50-64 year-olds [RR 0.84, 95% CI 0.77-0.93], and ≥ 65 year-olds [RR 0.74, 95% CI 0.58-0.95]). Conclusions: Consistent and significant decreases in both overall and VT IPD in children occurred quickly and were sustained for 7 years after PCV7 introduction, supporting use of PCVs. Increases in NVT IPD occurred in most sites, with variable magnitude. These findings may not represent the experience in low-income countries or the effects after introduction of higher valency PCVs. High-quality, population-based surveillance of serotype-specific IPD rates is needed to monitor vaccine impact as more countries, including low-income countries, introduce PCVs and as higher valency PCVs are used. Please see later in the article for the Editors' Summary.